CNR1 and metabolic disease: This study predisposes the fads2−/− mouse mutant as an unbiased mouse model for the discovery of therapeutically useful CB1 agonists and antagonists in the therapy of CNS-dysregulated feeding behavior and for metabolic diseases, including obesity and diabetes.